. Author manuscript; available in PMC: 2020 Feb 10.

Published in final edited form as: Ann N Y Acad Sci. 2015 Mar;1338:1–15. doi: 10.1111/nyas.12723

Table 3.

Summary of recent clinical trials on novel oral anticoagulants

Atrial fibrillation	Drug	Comparison	Primary end point: stroke and systemic embolism	ICH rate (% per year)	Major bleeding event (% per year)
RE-LY¹⁴	Dabigatran 150 mg BID or 110mg BID	Dose-adjusted warfarin	1.71% warfarin 1.54% dabigatran 110mg (P = 0.34) 1.11% dabigatran 150 mg (P< 0.001)	0.74% warfarin 0.23% dabigatran 110mg (P< 0.001) 0.3% dabigatran 150 mg (P< 0.001)	3.57% warfarin 2.87% dabigatran 110mg (P = 0.003) 3.32% dabigatran 150 mg (P=0.31)
ROCKET AF⁹	Rivaroxaban 20 mg once a day	Dose-adjusted warfarin	2.42% warfarin 2.12% rivaroxaban (P=0.117)	0.74% warfarin 0.49% rivaroxaban (P= 0.019)	3.45% warfarin 3.6% rivaroxaban (P= 0.576)
ARISTOTLE¹⁶	Apixaban 5 mg BID	Dose-adjusted warfarin	1.60 warfarin 1.27% apixaban (P< 0.001)	0.47% warfarin 0.24% apixaban	3.09% warfarin 2.13% apixaban (P< 0.001)
AVERROES¹⁹	Apixaban 5 mg BID	Aspirin (81–324 mg daily)	3.9% aspirin 1.7% apixaban (P< 0.001)	0.3% aspirin 0.4% apixaban (P=0.83)	1.2% aspirin 1.4% apixaban (P=0.33)

RE-LY, Randomized Evaluation of Longterm Anticoagulant Therapy; ROCKET-AF, Rivaroxaban Once daily oral direct factor Xa inhibition compared with vitamin K antagonism for prevention of stroke and Embolism Trial in Atrial Fibrillation; ARISTOTLE, Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation; AVERROES, Apixaban versus aspirin to reduce the risk of stroke; mg, milligram; BID, twice a day.